RaySearch Laboratories (RAY) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
30 Apr, 2026Executive summary
Q1 2026 saw net sales decline to SEK 290 million, down 20% year-over-year, mainly due to currency effects and a tough comparison with a large prior-year order from China, but profitability remained robust with an operating profit of SEK 68 million and a 23% margin.
Recurring support revenue provided stability, accounting for 42% of total revenue.
Several strategically important deals were secured, including first RayCare orders in China and France, and continued conversions in Germany; RayStation began treating patients in Ukraine.
Demand for integrated and automated cancer care workflows remains strong, with a solid sales pipeline and growing interest in online adaptive solutions.
The company is preparing for the first online adaptive treatments with RayStation, RayCare, and TrueBeam.
Financial highlights
Net sales declined 20% year-over-year to SEK 290 million, with organic growth at -5%.
Order intake dropped 13% compared to last year, affected by currency and a strong prior-year quarter.
Book-to-bill ratio was 1.2; order backlog at end of March was SEK 1,615 million, with SEK 624 million expected to convert to sales in the next 12 months.
License sales decreased 24% and support sales by 1% year-over-year; support revenue would have grown 8% excluding currency effects.
Cash balance at quarter-end was SEK 439 million; cash flow was stable despite inventory pre-purchasing to mitigate hardware price increases.
Outlook and guidance
Several delayed orders are expected to be recognized in Q2 or Q3, supporting a return to growth.
Confident in achieving at least a 25% operating margin for full year 2026 and a new long-term target of at least 30% by 2028.
No concerns about growth fading in 2027 despite Pinnacle³ conversion window closing.
Management expects continued strong demand for integrated and automated cancer care workflows, with a robust sales pipeline.
Revenues may fluctuate quarterly, but the long-term growth trend is positive.
Latest events from RaySearch Laboratories
- Record sales, strong margins, and major clinical milestones drive confidence for 2026.RAY
Q4 202512 Feb 2026 - Record sales, strong margins, and robust backlog signal continued growth and innovation.RAY
Q2 20241 Feb 2026 - Record Q3 sales, margin growth, and RayCare milestones prompt a higher 2026 target.RAY
Q3 202415 Jan 2026 - Record sales, profit, and margin growth drive higher dividend and upgraded margin target.RAY
Q4 202423 Dec 2025 - Q2 sales and profit declined, but strong H1 order intake and support revenue support a positive outlook.RAY
Q2 202523 Nov 2025 - Record Q1 sales, strong order intake, and margin expansion signal robust growth momentum.RAY
Q1 202520 Nov 2025 - Record Q3 sales and profit, with strong order intake and accelerating Pinnacle conversions.RAY
Q3 20257 Nov 2025